Academic-Industry Partnerships: Transparency, Potential Conflict of Interest, and Communicating State-of-the-Art Technologies
Bibliographic record
Abstract
Converting basic science discoveries into tangible diagnostic tools and therapies for human diseases is simultaneously valuable and daunting.Always looming in the background is the potential that translatable research knowledge may have commercial value in addition to its clinical and societal value.The researchers must determine what, if anything, should be done to ensure appropriate and fair retention of rights to their work and discoveries.In previous eras, when a scientist made a discovery in the laboratory that showed clinical utility, the potential for financial benefit was at best an indirect consideration.The most striking example may have been the transfer in 1923 of all commercial rights for insulin from the Canadian scientists who discovered it to their home university for a nominal $1 payment (1).More recently in the United States (US), scientists' motivation to hypothesize, experiment and discover opportunities to intervene on human disease was transformed in 1980 by passage of the Bayh-Dole Act (2).This watershed legislation irrevocably changed the pathway from research to commercialization (2).Previously, US grantee institutions assigned patents emanating from research activities to the federal government.After Bayh-Dole, academic and federally-funded institutions retained the ability to identify patentable discoveries from investigator-driven research and to forge ahead with patenting and development.This balanced the need to expeditiously bring a discovery into the clinical
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.029 | 0.151 |
| Meta-epidemiology (narrow) | 0.001 | 0.001 |
| Meta-epidemiology (broad) | 0.002 | 0.001 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.009 | 0.010 |
| Scholarly communication | 0.016 | 0.013 |
| Open science | 0.003 | 0.005 |
| Research integrity | 0.167 | 0.087 |
| Insufficient payload (model declined to judge) | 0.010 | 0.004 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".